Why the study?
Does low-dose systemic alteplase (tPA) provide safe and effective treatment in patients with acute pulmonary embolism?
Does low-dose systemic alteplase (tPA) provide safe and effective treatment in patients with acute pulmonary embolism?
Low-dose systemic tPA may be a safe and effective treatment for acute pulmonary embolism, especially in patients at high risk of bleeding.
Should not yet change practice in acute PE; leaves open low-dose tPA evaluation in high-bleed-risk patients via RCTs.
The available data suggest that low-dose tPA may be a safe and effective treatment option for acute PE, particularly in patients at a high risk of bleeding. More studies are needed to determine the optimal dosing regimen of tPA for PE.
No takes yet. Share an insight, caveat, or question.
Brandt et al. (2015) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: